Dr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.
- Revenue
- −10.1%
- EPS
- −36.8%
- Free cash flow
- −70.5%
- Total debt
- +14.1%
Quarter to September 2026, against a year earlier
Follow RDY
Alert me
Dr. Reddy's Laboratories Ltd (RDY) EV/FCF
As of 5 November 2026, Dr. Reddy's Laboratories Ltd (RDY) trades at a EV/FCF of 126×. Over the past ten years it has ranged from −42.6× (November 2016) to 562× (October 2024); the current reading is higher than 95% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2026 | 53.1× | (23.16%) |
| FY2025 | 69.1× | 37.40% |
| FY2024 | 50.3× | 176.66% |
| FY2023 | 18.2× | (67.38%) |
| FY2022 | 55.7× | 74.80% |
| FY2021 | 31.9× | 53.99% |
| FY2020 | 20.7× | (3.06%) |
| FY2019 | 21.4× | (60.04%) |
| FY2018 | 53.5× | — |
| FY2017 | −24.0× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 109× | 34.69% |
| Jun 2026 | 80.9× | 52.38% |
| Mar 2026 | 53.1× | 32.72% |
| Dec 2025 | 40.0× | (23.55%) |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −158× |
| NBIX Neurocrine Biosciences, Inc. compare | 15.5× |
| VTRS Viatris Inc. compare | 16.3× |
| LNTH Lantheus Holdings, Inc. compare | 16.6× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 32.2× |
| ALKS Alkermes plc compare | 36.0× |
| ELAN Elanco Animal Health Incorporated compare | 42.7× |
| HIMS Hims & Hers Health, Inc. compare | 73.6× |
| RDY Dr. Reddy's Laboratories Ltd | 126× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on RDY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement